Eplerenone Clinical Trials

Size	Price	Qty
10mg	USD 147
100mg	USD 370

Clinical Trials

Numerous clinical trials spanning Early Phase 1 through Phase 4 evaluate eplerenone across diverse conditions, including primary hypertension, left ventricular hypertrophy, paroxysmal atrial fibrillation, systemic proinflammatory states, and cardiotoxicity in breast cancer patients. Sponsored by academic medical centers such as Brigham and Women's Hospital and Assiut University alongside pharmaceutical companies like AstraZeneca and Bayer, these studies range from bioequivalence evaluations in healthy subjects to therapeutic efficacy trials in cardiac populations. Trial statuses encompass actively recruiting, completed, terminated, and upcoming investigations.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07727252	NOT_YET_RECRUITING	Subclinical Primary Aldosteronism	Xinjiang Medical University	2026-08-01	PHASE2; PHASE3
NCT07238400	RECRUITING	Hypertension	Massachusetts General Hospital	2026-03-20	PHASE2
NCT03984591	ENROLLING_BY_INVITATION	Systolic Heart Failure	Bispebjerg Hospital	2020-11-01	PHASE4
NCT05797558	RECRUITING	Primary Hyperaldosteronism Due to Adrenal Adenoma	Göteborg University	2023-04-28
NCT07345845	ACTIVE_NOT_RECRUITING	Preeclampsia; Preeclampsia Postpartum	Anna Stanhewicz, PhD	2025-12-17	EARLY_PHASE1
NCT05593055	RECRUITING	Hypertension; Left Ventricular Hypertrophy	Brigham and Women's Hospital	2023-08-25	PHASE4
NCT07795762	NOT_YET_RECRUITING	Intraocular Pressure (IOP); Healthy Adult	University of Florida	2026-10-01	PHASE1
NCT07029503	RECRUITING	HFrEF - Heart Failure With Reduced Ejection Fraction; Chronic Kidney Disease	Karolinska Institutet	2026-02	PHASE2
NCT06749418	RECRUITING	Preeclampsia; Preeclampsia Postpartum	Anna Stanhewicz, PhD	2025-01-02	EARLY_PHASE1
NCT05030545	RECRUITING	Primary Aldosteronism; Hypertension	Brigham and Women's Hospital	2022-12-15	PHASE4
NCT06168994	NOT_YET_RECRUITING	Paroxysmal Atrial Fibrillation	Assiut University	2024-02-01	PHASE4
NCT05198791	RECRUITING	Myocardial Infarction, Acute; Myocardial Infarction With Nonobstructive Coronary Arteries; Myocardial Injury	NHS National Waiting Times Centre Board	2022-02-04	PHASE2
NCT06275763	UNKNOWN	Hypertension	National Institute of Cardiology, Warsaw, Poland	2023-10-20	PHASE4
NCT03418649	WITHDRAWN	Degenerative Intervertebral Discs; Sciatic Radiculopathy; Low Back Pain	University of Cincinnati	2023-06	PHASE4
NCT04450953	RECRUITING	Kidney Transplantation for More Than One Year; Patients with a Kidney Transplantation on Cyclosporine	Central Hospital, Nancy, France	2021-10-12	PHASE3
NCT04519164	COMPLETED	Metabolic Syndrome; Hypertension; Overweight and Obesity	Brigham and Women's Hospital	2020-12-01	PHASE4
NCT04840342	ACTIVE_NOT_RECRUITING	Hypertension; Mineralocorticoid Excess	Brigham and Women's Hospital	2022-02-03	PHASE4
NCT03476616	COMPLETED	Hypertension; Obesity	Hippocration General Hospital	2018-09-01	PHASE4
NCT06208072	UNKNOWN	Primary Hypertension; Obesity	Hippocration General Hospital	2023-09-01
NCT06556732	UNKNOWN	Atrial Fibrillation	Assiut University	2024-08-10	PHASE1
NCT06649409	COMPLETED	Pharmacodynamic	Santhera Pharmaceuticals	2024-06-05	PHASE1
NCT06168994	Not yet recruiting	Paroxysmal Atrial Fibrillation	Assiut University	2024-02-01	Phase 4
NCT06208072	Recruiting	Primary Hypertension\|Obesity	Hippocration General Hospital\|National and Kapodistrian University of Athens	2023-09-01	Not Applicable
NCT03683069	COMPLETED	Hypertension; Genetics Hypertension	Brigham and Women's Hospital	2019-01-15	PHASE4
NCT04746495	WITHDRAWN	Hypertension	University of Michigan	2023-02	PHASE4
NCT02740179	COMPLETED	HIV	Massachusetts General Hospital	2017-01
NCT04697485	WITHDRAWN	HF - Heart Failure; Diabetes Mellitus	Northwestern University	2021-01-08	PHASE4
NCT05663372	COMPLETED	Bioequivalence; Healthy Subjects	Darnitsa Pharmaceutical Company	2021-12-07	PHASE1
NCT02490904	ACTIVE_NOT_RECRUITING	End-stage Renal Disease	Central Hospital, Nancy, France	2016-10-19	PHASE3
NCT02525796	COMPLETED	Primary Hyperparathyroidism	Brigham and Women's Hospital	2016-01	PHASE2; PHASE3
NCT01857856	COMPLETED	Phospholamban R14del Mutation-related Cardiomyopathy	M.p. van den Berg, MD, PhD, professor in Cardiology	2013-05	PHASE3
NCT01996449	COMPLETED	Hypertension	University of Texas Southwestern Medical Center	2013-07	PHASE2
NCT04300881	TERMINATED	Vitreomacular Traction; Subretinal Edema	Wagner Macula & Retina Center	2019-10-04	PHASE2
NCT01832558	UNKNOWN	CKD II-III	Medical University of Vienna	2012-11
NCT03165240	COMPLETED	Diabetic Nephropathies	Boehringer Ingelheim	2017-10-05	PHASE1
NCT03923530	COMPLETED	Hypertension; Aortic Stenosis, Calcific; Quality of Life; Heart Failure With Preserved Ejection Fraction	North Florida Foundation for Research and Education	2019-06-03	EARLY_PHASE1
NCT03017703	COMPLETED	Endothelial Dysfunction; Insulin Resistance	University of Southern Denmark	2016-12-01
NCT02871648	COMPLETED	Healthy Volunteers	Brigham and Women's Hospital	2016-01	PHASE1
NCT03079141	UNKNOWN	Chronic Central Serous Chorioretinopathy	Leiden University Medical Center	2017-02-20	PHASE4
NCT02345590	UNKNOWN	Aortic Aneurysm, Abdominal	Bayside Health	2015-05	PHASE4
NCT01887119	TERMINATED	Abdominal Obesity Metabolic Syndrome; Insulin Resistance; Hypertension	Maastricht University Medical Center	2013-10	PHASE4
NCT02354352	COMPLETED	Duchenne Muscular Dystrophy	Ohio State University	2015-03-20	PHASE3
NCT02957435	WITHDRAWN	Pharmacokinetics; Healthy Subjects; Fasting	Biolab Sanus Farmaceutica	2017-07	PHASE1
NCT02809963	COMPLETED	Diabetes Type 2	Herlev Hospital	2015-11	PHASE4
NCT02629094	TERMINATED	Cardiac Steatosis; Hepatic Steatosis	National Institute of Allergy and Infectious Diseases (NIAID)	2015-12-02	PHASE2
NCT01794091	WITHDRAWN	Diabetes Mellitus, Type II	Brigham and Women's Hospital	2013-08	PHASE4
NCT02890173	COMPLETED	Essential Hypertension	Daiichi Sankyo Co., Ltd.	2016-09	PHASE3
NCT01405456	COMPLETED	HIV	Massachusetts General Hospital	2012-01
NCT01822561	COMPLETED	Central Serous Chorioretinopathy	Tufts Medical Center	2013-05	PHASE2
NCT02215330	UNKNOWN	Central Serous Chorioretinopathy	Prim. Prof. Dr. Oliver Findl, MBA	2014-10	PHASE2; PHASE3
NCT03186742	COMPLETED	Hypertension,Essential; Obstructive Sleep Apnea; Left Ventricular Hypertrophy	Poznan University of Medical Sciences	2014-07-01	PHASE4
NCT00223717	COMPLETED	Hypertension	Vanderbilt University	2001-01	PHASE1
NCT01708798	TERMINATED	Breast Cancer	University of British Columbia	2014-05	PHASE2; PHASE3
NCT02607657	WITHDRAWN	Healthy Volunteers	Biolab Sanus Farmaceutica	2016-05	PHASE1
NCT02462499	COMPLETED	Chronic Central Serous Chorioretinopathy	Semmelweis University	2014-06	PHASE4
NCT01394627	COMPLETED	Hypoglycemia	Brigham and Women's Hospital	2011-01
NCT01521546	COMPLETED	Duchenne Muscular Dystrophy	Subha Raman	2012-02
NCT01971593	TERMINATED	Tetralogy of Fallot; Transposition of the Great Vessels With an Arterial Switch; Single Ventricle With a Fontan Palliation	Washington University School of Medicine	2013-08	PHASE4
NCT01893788	UNKNOWN	Hypertensive Left Ventricular Hypertrophy	Nagoya University	2013-04	PHASE4
NCT02118753	COMPLETED	Ischemia-reperfusion Injury	Radboud University Medical Center	2014-03
NCT02532998	COMPLETED	Pharmacodynamics; Healthy Subjects	AstraZeneca	2015-09	PHASE1
NCT01801228	WITHDRAWN	Ascites; Cirrhosis	Emma Nilsson	2013-02	PHASE2
NCT01115855	COMPLETED	Heart Failure	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2010-07	PHASE3
NCT02345044	COMPLETED	Essential Hypertension	Daiichi Sankyo	2015-01	PHASE2
NCT02153125	UNKNOWN	Central Serous Chorioretinopathy	Tel-Aviv Sourasky Medical Center	2014-04	PHASE2
NCT01990677	COMPLETED	Central Serous Chorioretinopathy	Wills Eye	2013-10
NCT01586442	COMPLETED	Heart Failure; Type 2 Diabetes; Glucose Intolerance	Montreal Heart Institute	2012-03	PHASE3
NCT01955694	COMPLETED	Heart Failure	Bayer	2013-11-11	PHASE2
NCT01275352	WITHDRAWN	Hypertension	Washington University School of Medicine	2011-12	PHASE4
NCT01807221	COMPLETED	Heart Failure	Bayer	2013-06-17	PHASE2
NCT00825188	TERMINATED	Obesity; Hypertension	University of Mississippi Medical Center	2009-01
NCT01650012	COMPLETED	Hemodialysis; End Stage Renal Disease	McMaster University	2013-03
NCT01837108	COMPLETED	Pharmacodynamics	Radboud University Medical Center	2013-04	PHASE4
NCT00401856	COMPLETED	Cardiomyopathy	Royal Brompton & Harefield NHS Foundation Trust	2007-12	PHASE4
NCT01834768	UNKNOWN	Chronic Kidney Insufficiency; Kidney Transplantation	CHU de Reims	2013-02	PHASE2
NCT01427972	COMPLETED	Chronic Kidney Disease	Eli Lilly and Company	2011-09	PHASE2
NCT01786551	COMPLETED	Systemic Proinflammatory State	Brigham and Women's Hospital	2010-03
NCT01319344	COMPLETED	Metabolic Syndrome; Endothelial Dysfunction	University of Erlangen-Nürnberg Medical School	2010-09	PHASE3
NCT01176968	COMPLETED	Myocardial Infarction	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2010-09	PHASE4
NCT01302236	WITHDRAWN	Hypertension; Chronic Kidney Disease.	Jichi Medical University	2011-03	PHASE4
NCT00647192	TERMINATED	Atrial Fibrillation	University Hospital, Saarland	2008-03	PHASE2
NCT01100203	TERMINATED	Chronic Kidney Disease	Lene Boesby	2010-04	PHASE3
NCT01373086	TERMINATED	Hypertension	Novartis Pharmaceuticals	2011-05	PHASE2
NCT00980031	TERMINATED	Myocardial Remodeling	Creighton University	2007-04
NCT00315016	COMPLETED	Diabetic Nephropathy	Radboud University Medical Center	2007-01	PHASE2
NCT01237899	COMPLETED	Chronic Kidney Disease	Eli Lilly and Company	2010-10	PHASE1
NCT00703352	COMPLETED	Transposition of Great Vessels; Atrial Switch Procedure	Hospital Universitari Vall d'Hebron Research Institute	2008-07	PHASE4
NCT01473108	COMPLETED	Clinical Pharmacology	Bayer	2010-03-29	PHASE1
NCT00232180	COMPLETED	Heart Failure	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2006-03	PHASE3
NCT00515021	COMPLETED	Metabolic Syndrome X	Vanderbilt University Medical Center	2007-04	PHASE4
NCT00990223	COMPLETED	Healthy Volunteers	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2009-10	PHASE1
NCT00817635	COMPLETED	Hypertension	Novartis	2008-12-22	PHASE2
NCT00430924	COMPLETED	Kidney Failure, Chronic	Lene Boesby	2007-03	PHASE4
NCT00758524	COMPLETED	Essential Hypertension	Novartis Pharmaceuticals	2008-09-11	PHASE2
NCT00608465	TERMINATED	Metabolic Syndrome X	Vanderbilt University	2006-05	PHASE4
NCT00187889	COMPLETED	Ischemic Heart Disease	University of Florida	2004-08	PHASE4
NCT00391846	COMPLETED	Heart Failure; Ventricular Dysfunction, Left	AstraZeneca	2006-10	PHASE4
NCT00505336	COMPLETED	Diastolic Heart Failure	St Vincent's University Hospital, Ireland	2006-04
NCT00138944	COMPLETED	Essential Hypertension	University of Erlangen-Nürnberg Medical School	2007-01	PHASE3
NCT00108251	COMPLETED	Congestive Heart Failure; Diastole	US Department of Veterans Affairs	2004-08	PHASE4
NCT00293150	TERMINATED	Diastolic Heart Failure	The Cleveland Clinic	2003-09	PHASE4
NCT00865618	COMPLETED	Hypertension	Sandoz	2006-06	PHASE1
NCT00865176	COMPLETED	Hypertension	Sandoz	2006-06	PHASE1
NCT00147563	COMPLETED	Hypertension	Pfizer	2003-10	PHASE4
NCT00214825	COMPLETED	Diabetes Mellitus; Endothelial Dysfunction; Albuminuria	Brigham and Women's Hospital	2003-08
NCT00147615	COMPLETED	Hypertension	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2004-10	PHASE3
NCT00553722	UNKNOWN	Hypertension; Dialysis; Hyperaldosteronism	Shaare Zedek Medical Center	2007-11	PHASE4
NCT00132093	COMPLETED	Myocardial Infarction	NHS Greater Glasgow and Clyde	2005-04	PHASE4
NCT00082589	COMPLETED	Heart Failure, Congestive	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2004-04	PHASE4
NCT00147589	COMPLETED	Hypertension	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2004-09	PHASE3
NCT00649311	TERMINATED	Hypertension	Pfizer	2003-04	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-07-27)

Check the Eplerenone product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Eplerenone selectively binds to the mineralocorticoid receptor, competitively blocking the actions of aldosterone to prevent renal sodium retention and downstream cardiovascular inflammatory signaling. This target blockade reduces intravascular volume and pathological vascular remodeling, ultimately lowering systemic blood pressure and blunting adverse cardiac remodeling in clinical conditions such as hypertension and left ventricular hypertrophy.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).